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Across  human  and  veterinary  medicine,  vaccines  against  only  two  retroviral  infections  have  been brought
to  market  successfully,  the  vaccines  against  feline  leukaemia  virus  (FeLV)  and  feline  immunodeﬁciency
virus  (FIV).  FeLV  vaccines  have  been  a  global  success  story,  reducing  virus  prevalence  in countries  where
uptake  is high.  In  contrast,  the  more  recent  FIV  vaccine  was  introduced  in 2002  and  the  degree  of  protec-
tion  afforded  in the  ﬁeld  remains  to be  established.  However,  given  the  similarities  between  FIV  and  HIV,
ﬁeld studies  of  FIV  vaccine  efﬁcacy  are  likely  to advise  and  inform  the  development  of  future  approaches
to  HIV vaccination.
Here we assessed  the neutralising  antibody  response  induced  by FIV  vaccination  against  a  panel  of  FIVaccine induced protection
eutralising antibodies
isolates,  by testing  blood  samples  collected  from  client-owned  vaccinated  Australian  cats.  We  examined
the  molecular  and  phenotypic  properties  of  24  envs  isolated  from  one  vaccinated  cat  that  we speculated
might  have  become  infected  following  natural  exposure  to FIV.  Cats  vaccinated  against  FIV  did  not  display
broadly  neutralising  antibodies,  suggesting  that  protection  may  not  extend  to  some  virulent  recombinant
strains  of FIV  circulating  in  Australia.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
Throughout the history of retroviral vaccine development, only
wo vaccines have made it to market, the vaccines for the feline
etroviruses FIV and FeLV. FeLV vaccines were introduced over
hirty years ago and since then have made a signiﬁcant impact upon
he prevalence of infection [1]. The ﬁrst FIV vaccine was introduced
n the US in 2002. Fel-O-Vax FIV (Boehringer-Ingelheim) induces
Abbreviations: FIV, feline immunodeﬁciency virus; FeLV, feline leukaemia virus;
Ab, neutralising antibody; RT, reverse transcriptase; GARD, genetic algorithm
ecombination detection; ML,  maximum likelihood; NJ, neighbour joining; AIC,
kaike information criterion; bp, base pair.
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
80% protection against experimental [2] and contact challenge [3],
with protection also extending to heterologous challenge [4]. Given
the similarities between FIV infection of cats and HIV infection of
humans, a broader understanding of the mechanisms of immunity
to infection with FIV may  inform the development of candidate HIV
vaccines. An effective HIV vaccine has proved elusive [5] and the
insights offered by the study of retroviral immunity in other species
may  direct future research efforts along a more fruitful pathway.
The success of FeLV vaccines may  reﬂect the ability of a pro-
portion of cats to recover from natural infection. In contrast with
FeLV, spontaneous resolution of infection has been documented
in neither HIV nor FIV infection [6,7], posing a major obstacle to
lentiviral vaccine development. Numerous experimental HIV vac-
cine candidates have been developed, with outcomes ranging from
complete protection to enhancement of infection [5]. Four HIV vac-
cines were advanced from testing in non-human primate models
to phase IIb or III efﬁcacy trials in human volunteers [8,9]. These
included VaxGen gp120 (B/B′ and B/E) tested in trials in the USA
[10,11] and Thailand [12], the Merck Ad5-HIV-1 tested in the STEP
trial [13,14] and ALVAC + gp120 tested in the RV144 study [15]. The
Merck vaccine trial was halted prematurely when it became evident
that vaccination increased the risk of HIV acquisition [16], but most
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
9  Vaccine 33 (2015) 977–984
p
T
s
s
s
l
t
r
i
[
a
e
F
h
N
F
r
e
p
e
f
2
2
U
2
V
J
F
s
b
(
2
g
F
a
(
a
2
w
P
m
s
f
(
t
t
w
C
o
t
p
u
e
p
t
u
or
y 
of
 
Fe
l-
O
-V
ax
 
FI
V
 
va
cc
in
at
ed
 
ca
ts
. A
ge
 
is
 
ac
cu
ra
te
 
fo
r 
th
e 
bl
oo
d
 
sa
m
p
le
 
co
ll
ec
ti
on
 
d
at
es
. A
ll
 
ca
ts
 
w
er
e 
te
st
ed
 
bo
th
 
by
 
FI
V
 
EL
IS
A
 
an
d
 
FI
V
 
PC
R
, w
it
h
 
th
e 
ex
ce
p
ti
on
 
of
 
tw
o 
ca
ts
 
ke
p
t 
en
ti
re
ly
 
in
d
oo
rs
, w
h
ic
h
 
w
er
e 
te
st
ed
O
n
e 
va
cc
in
at
ed
 
ca
t,
 
SV
1 
te
st
ed
 
p
os
it
iv
e 
fo
r 
FI
V
 
p
ro
vi
ra
l 
D
N
A
, w
h
il
e 
al
l 
ot
h
er
s 
w
er
e 
n
eg
at
iv
e.
 
B
re
ed
: 
D
SH
—
d
om
es
ti
c 
sh
or
t 
h
ai
r,
 
D
M
H
—
d
om
es
ti
c 
m
ed
iu
m
 
h
ai
r,
 
D
LH
—
d
om
es
ti
c 
lo
n
g 
h
ai
r.
 
Se
x:
 
F—
fe
m
al
e,
 
FS
—
fe
m
al
e
—
m
al
e 
n
eu
te
re
d
. H
ou
si
n
g:
 
I—
in
d
oo
r,
 
O
—
ou
td
oo
r.
 
y—
ye
ar
s.
 
n
/a
—
n
ot
 
av
ai
la
bl
e.
re
ed
 
Se
x 
A
ge
 
(y
) 
H
ou
si
n
g 
EL
IS
A
 
PC
R
 
D
at
e 
of
 
PC
R
te
st
in
g
D
at
e 
of
 
FI
V
va
cc
in
at
io
n
B
lo
od
co
ll
ec
ti
on
C
h
ie
f c
om
p
la
in
t 
D
ia
gn
os
is
 
O
th
er
SH
 
M
N
 
11
 
I/
O
 
+ 
+ 
15
.1
2.
09
 
O
ct
 
20
06
, N
ov
 
20
07
,
O
ct
 
20
08
, S
ep
 
20
09
09
.1
2.
09
 
N
o 
n
as
al
 
an
d
 
fa
ci
al
 
se
n
sa
ti
on
,
d
ro
ol
in
g  
sa
li
va
Tr
ig
em
in
al
 
n
er
ve
 
p
ar
al
ys
is
,
ca
ve
rn
ou
s  
si
n
u
s 
sy
n
d
ro
m
e
R
en
om
eg
al
y,
 
ﬁ
gh
ts
,
u
n
kn
ow
n
 
FI
V
 
st
at
u
s
at
 
th
e 
ﬁ
rs
t
va
cc
in
at
io
n
M
H
 
FS
 
10
 
I/
O
 
+ 
− 
26
.1
1.
08
 
O
ct
 
20
08
 
19
.1
1.
08
 
Le
th
ar
gy
 
an
d
 
in
ap
p
et
en
ce
 
A
n
ae
m
ia
, h
ep
at
it
is
,
sp
le
n
om
eg
al
y,
in
ﬂ
am
m
at
or
y  
bo
n
e 
m
ar
ro
w
d
is
ea
se
–
ag
d
ol
l 
FS
 
3 
I 
+ 
− 
02
.1
1.
09
 
R
eg
u
la
rl
y 
si
n
ce
ki
tt
en
06
.0
5.
10
 
Le
th
ar
gy
, i
n
ap
p
et
en
ce
 
an
d
w
ei
gh
t  
lo
ss
Id
io
p
at
h
ic
 
h
yp
er
ca
lc
em
ia
 
R
en
al
 
in
su
fﬁ
ci
en
cy
u
rm
es
e 
M
N
 
6 
I/
O
 
+ 
− 
13
.0
5.
09
 
U
n
kn
ow
n
 
25
.0
6.
09
 
Le
th
ar
gy
, d
ep
re
ss
io
n
, w
ei
gh
t
lo
ss
,  m
u
lt
ip
le
 
jo
in
t 
ef
fu
si
on
Po
ly
ar
th
ri
ti
s,
 
im
m
u
n
e
m
ed
ia
te
d
 
(?
)
Fi
gh
t 
w
ou
n
d
s
by
ss
in
ia
n
 
M
N
 
10
 
I/
O
 
+ 
− 
15
.0
7.
09
 
R
eg
u
la
rl
y,
 
la
st
 
on
e
Ja
n
 
20
09
23
.0
7.
09
 
Sn
ee
zi
n
g,
 
oc
u
la
r 
an
d
 
n
as
al
d
is
ch
ar
ge
A
ct
iv
e 
ch
ro
n
ic
 
rh
in
it
is
 
–
SH
 
FS
 
9 
I 
+ 
− 
16
.1
0.
09
 
U
n
kn
ow
n
 
14
.1
0.
09
 
Su
d
d
en
 
on
se
t 
at
ax
ia
 
M
en
in
gi
om
a,
 
ri
gh
t 
oc
ci
p
it
al
lo
be
–
LH
 
M
N
 
12
 
I/
O
 
+ 
− 
09
.0
3.
10
 
U
n
kn
ow
n
 
02
.0
3.
10
 
Pr
es
en
te
d
 
fo
r 
ra
d
io
-i
od
in
e
tr
ea
tm
en
t
H
yp
er
th
yr
oi
d
is
m
 
–
SH
 
M
N
 
6 
I/
O
 
+ 
− 
U
n
kn
ow
n
 
U
n
kn
ow
n
 
26
.1
0.
10
 
Sw
ol
le
n
 
le
ft
 
h
in
d
 
le
g 
N
on
-r
eg
en
er
at
iv
e 
an
ae
m
ia
 
Fi
gh
t 
w
ou
n
d
s
SH
 
FS
 
8 
I 
n
/a
 
− 
15
.1
2.
14
 
R
eg
u
la
rl
y 
si
n
ce
ki
tt
en
30
.0
4.
09
 
A
cu
te
 
vo
m
it
in
g 
Pa
n
cr
ea
ti
ti
s 
–
ri
ti
sh
 
sh
or
t 
h
ai
r 
F 
1 
I 
n
/a
 
− 
15
.1
2.
14
 
O
n
ce
 
as
 
a 
ki
tt
en
 
20
.0
7.
09
 
Py
re
xi
a,
 
le
th
ar
gy
, i
n
ap
p
et
en
ce
 
Ef
fu
si
ve
 
fe
li
n
e 
in
fe
ct
io
u
s
p
er
it
on
it
is
Eu
th
an
is
ed
fo
ll
ow
in
g  
d
ia
gn
os
is78 P.M. Be˛czkowski et al. /
romising was the 30% protection observed in the RV144 study [17].
hese contrasting ﬁndings raise the question: is our current under-
tanding of lentiviral biology and immune correlates of protection
ufﬁcient to design a safe and fully efﬁcacious lentiviral vaccine?
FIV provides a unique opportunity to conduct comparative
tudies to deﬁne the mechanisms of vaccine protection against
entivirus infection [18]. Several FIV vaccine candidates have been
ested, yielding valuable insights into the virus biology and cor-
elates of protection. To date, whole inactivated virus and ﬁxed
nfected-cell vaccines have proved to be the most successful
18–20], leading to the commercial production of the whole inactiv-
ted virus, dual-subtype FIV vaccine [2]. Following safety and
fﬁcacy evaluation by USDA (US Department of Agriculture), the
IV vaccine was launched in the US in 2002 [21] and subsequently
as been licensed for veterinary use in Canada (2003), Australia and
ew Zealand (2004) and Japan (2008).
Although a lack of protection against the pathogenic primary
IV isolate GL8 was evident experimentally [22], no independent
esearch has been published evaluating the commercial vaccine’s
fﬁcacy under ﬁeld conditions [4]. Here we identiﬁed rare sam-
les from client-owned cats that had been vaccinated against FIV,
valuating the breadth of neutralising antibodies (NAbs) induced
ollowing FIV vaccination.
. Materials and methods
.1. Blood samples
Samples used in this study were collected according to the
niversity of Sydney Animal Ethics Committee approvals (N00/6-
009/1/4985). A search of the electronic medical records of the
alentine Charlton Cat Centre (VCCC), University of Sydney from
anuary 2005 to September 2010 identiﬁed cats with a history of
IV vaccination. Informed owner consent was available (Univer-
ity of Sydney ethics approval number N00/6-2009/1/4985) to use
lood samples from 8 vaccinates of known ELISA and FIV PCR status
Gribbles Veterinary Laboratories, Victoria, Australia) and a further
 vaccinates tested negative using a quantitative PCR to detect FIV
ag (data not shown). One vaccinated cat (SV1) tested positive for
IV proviral DNA (Table 1). Blood samples were collected into hep-
rinised collection tubes. Samples were centrifuged at 2000 rpm
∼370 × g) for 10 min  and plasma and cell fractions were separated
nd stored frozen at −80 ◦C.
.2. Ampliﬁcation and cloning of FIV env
The complete FIV envs from cat SV1 were ampliﬁed directly from
hole blood using a nested PCR protocol (Table S1). First round
CR products were ampliﬁed using Phusion Blood Direct II Poly-
erase (Finnzymes, Thermo Fisher Scientiﬁc) and the nucleic acid
equence of the ﬁrst-round PCR product informed primer design
or the second round PCR, performed using High Fidelity Master
Roche). Strain-speciﬁc primers for the second round PCR reac-
ions incorporated restriction sites to facilitate sub-cloning into
he eukaryotic expression vector VR1012 [23]. Thus cloned envs
ere transformed into Escherichia Coli MAX  Efﬁciency® DH5TM
ompetent Cells (Invitrogen). In total, 24 clonal env variants were
btained from cat SV1; however, since sequence analysis revealed
hat 12/24 amplicons contained only synonymous mutations, we
roceeded to produce pseudotypes bearing the 12 Envs with
nique amino acid sequences. Therefore these twelve FIV env
xpression constructs were co-transfected transiently with HIV
NL4-3-Luc-E-R-luc plasmid (an env-deleted HIV provirus con-
aining a luciferase reporter gene) [24] into HEK 293T cells [25]
sing Superfect Transfection Reagent (Invitrogen). Following a 72 h T
ab
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Table  2
Classiﬁcation of neutralisation potency of plasma samples.
Neutralisation potency
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Table 3
Neutralisation potency of plasma samples from 10 vaccinated cats, expressed as
fold neutralisation. Samples were assessed against a panel of pseudotypes bearing 7
reference Envs (GL-8, [27]; B2542, [28]; PPR, [29]; CPG41, [30]; M2PET, [31] NCSU,
[32] and KKS, [33]) and 24 wild type Envs isolated from US cats that had been natu-
rally infected with FIV [26]. Phylogenetic classiﬁcation of the Env clade is included.
Weak, moderate or strong neutralisation is indicated in yellow, orange and red,
respectively. Sample volumes from cats SV2, SV3, SV6 and SV9 were limited and
were insufﬁcient for all analyses. n/a—Not available.
Pseudotype Cla de
Plasma sample
SV1 SV2 SV3 SV4 SV5 SV6 SV7 SV8 SV9 SV 10
GL8 A 2.4 1 2.5 2.2 1.8 1.1 1.4 0.9 1.1 1.3
B2542 B 2.4 1 3.5 2 2 1.5 1.1 1.3 1.2 1
PPR A 2.2 1.5 3.4 1.8 3.4 1.3 2.2 0.8 1.6 1.6
CPG41 C 1.2 1.3 3.9 2.8 2.5 1.1 1.8 0.9 1.4 0.7
M2PET A 2.2 0.7 1.8 1.9 2.3 1.2 1.4 0.9 1.1 1.3
NCSU A 2.6 1 2.8 1.9 2.2 1.2 1.5 0.7 1.3 1.1
KKS A 2.1 1.4 17.3 20.8 4.3 16.9 1.7 33 16.5 3
M15 B 2.5 0.5 0.8 3.3 2.6 n/a 2.5 1 2.9 0.7
M14 B 1 0.3 1.9 1.2 1.5 n/a 2.9 0.5 2.2 0.5
M5 B 2.1 0.9 1.5 3 6.2 n/a 2.8 1.3 1.2 2.2
M28 B 1.1 0.8 0.4 1.7 15.1 n/a 5 0.8 1.7 0.3
M30 B 3 0.3 1.6 2.4 4.2 n/a 2.1 1.2 1 1.9
M33 A/B 2.5 0.9 1.2 1.9 2.3 n/a 0.8 1.8 1.1 1.3
M44 B 3.4 1.2 1.6 1.7 3.6 n/a 1.6 2.3 1.5 1.8
M49 B 2.4 1.3 3.9 7.5 16.4 n/a 6.9 1.2 1 4.5
M50 A/B 3.1 1.2 0.9 1.3 2.3 n/a 0.9 1.8 0.9 1.7
M47 A/B 1.1 0.5 1 0.8 0.6 n/a 1.2 0.3 0.2 0.3
M16 B 2.1 1.2 1.6 1.7 3.1 n/a 1.5 1.4 1 2.2
M11 B 2.6 1.3 2 1.9 3.7 n/a 1.5 2.2 1.3 2.5
M26 B 2 1.8 1.8 1.7 2.8 n/a 1.7 2.4 1.8 1.8
M3 B 3.1 1.6 2 2.1 4.1 n/a 1.7 1.9 1.1 1.8
P2 B 3.8 2.3 n/a 4.6 4 n/a 4 5.7 2.9 3.2
P4 A/B 5.2 2.3 n/a 4.5 4.7 n/a 3.7 3.3 3.3 2.5
P6 B 5.6 2.8 n/a 6.1 5.1 n/a 4 4.1 2.3 3.5
P13 A/B 5.3 3 n/a 4.4 4.9 n/a 4.8 3.8 2.9 3.8
P14 A/B 88.7 n/a n/a 9.8 16.7 n/a 6 2.8 6.2 4.3
P17 B 3.1 n/a n/a 4.1 6.9 n/a 2.6 2.4 2.6 1.8
P9 B 3 n/a n/a 3 3.2 n/a 1.7 2.5 1.2 2
P10 B 5.2 n/a n/a 4.4 3.3 n/a 2.4 3.1 n/a 2.6Fold neutralisation 1–1.6 1.7–2.4 2.5–5.5 5.6–10 10,000
%  Neutralisation 0–39 40–59 60–80 81–90 100
ncubation in 6 well culture clusters (Corning), culture ﬂuids con-
aining HIV(FIV)-luciferase pseudotypes (hereafter referred to as
IV(FIV)-luc, with the FIV Env in parenthesis) were harvested, cen-
rifuged at 1000 rpm (∼200 × g) for 5 min, passed through 0.45 m
lters and stored at −80 ◦C until required. HIV(FIV) luciferase pseu-
otypes (n = 43) were prepared, bearing 12 Envs from cat SV1, 24
eld Envs isolated from 24 naturally infected American cats [26]
nd 7 reference FIV Envs reported previously [27–33], in order to
ssess neutralising antibody (NAb) responses in plasma samples
nd to determine the nature of the Env-receptor interaction.
.3. Neutralisation assays
Plasma samples from 10 vaccinated cats were tested for NAbs
gainst a panel of 31 HIV(FIV)-luc pseudotypes bearing heterolo-
ous Env (Table 3). The exceptions were samples from SV6, SV3,
nd SV2, which were limiting and could only be tested against
, 21 or 25 pseudotypes, respectively. Due to the high sequence
omology observed, pseudotypes bearing 12 SV1 Envs, represen-
ative of the 24 Envs cloned, were tested additionally for sensitivity
o autologous neutralisation.
Tenfold dilutions of each plasma sample were prepared in com-
lete RPMI 1640 medium (Invitrogen), from a starting dilution of
 in 10. Next, 25 l of each plasma dilution (1 in 10, 1 in 100 and
 in 1000) were incubated in triplicate for 1 h at 37 ◦C with 25 l
f HIV(FIV)-luc pseudotype before 5 × 104 of CLL-CD134 cells [34]
ere added in 50 l. Following a 72 h incubation in CulturPlateTM-
6 assay plates (Perkin Elmer), luciferase activity was quantiﬁed
y the addition of 100 l of Steadylite HTSTM (Perkin Elmer) sub-
trate and single photon counting, using a MicroBeta luminometer
Perkin Elmer). Fold neutralisation was calculated by dividing the
ean luciferase counts of control wells containing no plasma (NP
uc) with the mean luciferase counts for wells containing 1 in 10
lasma dilutions (P luc). Plasma samples were classiﬁed according
o neutralisation potency, using the cut-off values shown in Table 2.
.4. Assaying receptor utilisation
Feline cells expressing feline CD134 (MCC FFF), a chimaeric
uman × feline CD134 (MCC FFH) or human CD134 (MCC HHH)
34], and a canine cell line modiﬁed to express feline CD134 (CLL-
D134) [34], were seeded at 1 × 104 cells per well in triplicate in a
ulturPlateTM-96 assay plate (Perkin Elmer). The cells were infected
ith 50 l of each HIV (SV1)-luc pseudotype, alongside reference
ontrols of HIV (GL8)-luc and HIV (B2542)-luc. After incubation for
2 h at 37 ◦C in an atmosphere of 5% CO2, the luciferase activity was
uantiﬁed as described above.
.5. Sequences and phylogenetic analyses
Twenty-four VR1012 plasmids expressing SV1 FIV envs were
equenced using the Big Dye Terminator v1.1 kit. The full length
IV env sequence (approx. 2500 bp) from each clone was  assembled
sing 4 sequencing reads overlapping by approximately 200 bp
nd manually checked for mismatches. Nucleotide and peptide
equence alignment was performed using the Muscle algorithm
35] in MEGA5 [36]. Evolutionary divergence between sequences
as calculated using the Maximum Composite Likelihood modelP21 B 5.2 n/a n/a 3.7 4.7 n/a 2.9 2.5 n/a 3.8
P8 A/B 50.8 n/a n/a 3.4 2.7 n/a 2.3 3 n/a 1.9
[37]. A phylogenetic tree comprising the complete env sequences
was constructed using the maximum likelihood (ML) method under
HKY nucleotide substitution model [36] in MEGA5. Sequences
were analysed using the Datamonkey webserver [38], employing
the genetic algorithm recombination detection (GARD) method
[39]. Neighbour joining (NJ) trees for each recombination seg-
ment (identiﬁed by GARD and assessed by Akaike Information
Criterion (AIC) [40]) were prepared for presentation in FigTree
v 1.3.1 (http://tree.bio.ed.ac.uk/). A representative ﬁgure visu-
alizing recombination breakpoints was generated in SimPlot v
3.5.1 [41]. Highlighter analysis was performed using the high-
lighter tool available at the Los Alamos National Laboratory server
(www.hiv.lanl.gov). Graphs were created in GraphPad Prism v 5.00
(GraphPad Software).
3. Results
3.1. Breadth of the neutralizing antibody response in vaccinated
cats
To assess the breadth and strength of NAbs in cats vaccinated
with the Fel-O-Vax FIV vaccine, 10 plasma samples collected from
vaccinated ﬁeld cats were tested for neutralisation against a panel
of pseudotypes bearing a range of FIV Envs, including Envs from
reference subtype A, B and C isolates and primary ﬁeld isolates of
FIV (Table 3). Plasma samples from ten vaccinated cats displayed
variable neutralisation of the pseudotypes but plasma SV5 strongly
980 P.M. Be˛czkowski et al. / Vaccine 33 (2015) 977–984
Fig. 1. Neighbour joining trees for each of two  GARD determined segments of representative SV1 sequence; tree (A) represents phylogenetic inference of the ﬁrst segment
of  the env (1–483 bp) and tree (B) of the second segment (484–2562 bp). Both trees are based on: (1) one sequence representative of 24 env genes from cat SV1 (red tip),
(2)  43 entire env sequences from cats naturally infected with FIV in the US [26], from which the Envs were used to prepare pseudotypes for neutralisation studies in the
present  study and (3) 17 full length env sequences derived from GenBank; Aomori 1 [D37816], Aomori 2 [D37817.1], FIV C [AF474246.1], Dixon [L00608.1], Dutch [X60725],
Fukuoka [D37815.1], Sendai 1 [D37813.1], Shizuoka [D37811.1], UK2 [X69494.1], UK8 [X69496.1], USIL2489 [U11820.1], Yokohama [D37812.1], Petaluma [M25381.1], PPR
[M36968.1], Leviano [FJ374696.1], Bangston [AY620002.1] and FC1 [AY621093.1]. The ﬁrst segment of the SV1 env sequence (red tip) clusters with clade B isolates (green
nodes),  while the second segment (red tip) is more closely related to the clade A isolates (red nodes) that include GL8. Trees are rooted on the FIV clade C reference env
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eutralised ﬁve pseudotypes bearing Envs of US ﬁeld isolates, SV4
trongly neutralised four pseudotypes, one bearing the Env desig-
ated KKS and a further three bearing US ﬁeld isolate Envs and SV1
trongly neutralised three pseudotypes bearing Envs of US ﬁeld iso-
ates. The pseudotype bearing the Env designated KKS (clade A) was
losely related to FIV Petaluma Env (one of the isolates within the
IV vaccine) and was neutralised by nine of the ten plasma sam-
les tested. Three pseudotypes bearing Envs cloned from naturallyons per site. (For interpretation of the references to color in this ﬁgure legend, the
infected US cats (P14, clade A/B; M49, clade B; and P6, clade B)
were strongly neutralised by ﬁve, three and two  plasma samples,
respectively (Table 3).3.2. Vaccinated, provirus positive cat SV1: Phylogenetic inference
Twenty-four env sequences cloned from cat SV1 were identical,
or near identical, with an overall mean intra-host diversity of 0.1%
P.M. Be˛czkowski et al. / Vaccine 33 (2015) 977–984 981
F2 F3 F4 F7 F1
9
F2
0
F2
1
F2
2
F2
8
F3
2
F3
5
F3
6
P
8
P
10
P
14 M
5
M
44
M
49
G
L8
P
P
R
K
K
S
N
C
S
U
B
25
42
C
P
G
41
M
2P
E
T
1
10
100
1000
10000
FIV Env
SV1 ho mologou s pseudo type s
Chicago heterologous pseudotypes
Memph is he terologou s pseudo type s
Reference heterologous pseudotypes
Ne
ut
ra
lis
at
io
n 
(fo
ld
)
Fig. 2. Neutralisation of plasma SV1 against HIV(FIV)luc pseudotypes bearing: (1) 12 autologous SV1 Envs (blue circles), (2) 3 heterologous Envs representative of Memphis
ﬁeld  isolate Envs (red squares), (3) 3 heterologous Envs representative of Chicago ﬁeld isolate Envs (green triangles) and (4) 7 heterologous Envs of reference FIV isolates
(white  triangles). Fold neutralisation was calculated by dividing the mean luciferase counts of control wells containing no plasma with the mean luciferase counts for wells
containing 1 in 10 plasma dilutions. All pseudotypes bearing autologous Envs, but only three bearing heterologous Envs, were strongly neutralised by plasma SV1. For clarity,
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Fig. S3). Maximum likelihood analysis revealed that cat SV1 har-
oured viruses containing clade A envs (Fig. S4). However, following
igorous recombination testing, it was evident that all envs from
at SV1 were clade A/B recombinants. GARD analysis indicated one
reakpoint with signiﬁcant topological incongruence (p = 0.00120)
t position 483 of the nucleotide sequence alignment. Thus the ﬁrst
egment of GARD spliced env was assigned to Clade B while the
emaining fragment clustered together with clade A and was  rela-
ively closely related to the GL8 strain of FIV (K2P distance of 7%),
Fig. 1).
.3. Autologous neutralising antibody response
Plasma SV1 was one of three samples that displayed the
roadest heterologous neutralisation (Table 3). Compared to the
oderate heterologous neutralisation observed, SV1 strongly neu-
ralised all pseudotypes bearing autologous Envs (ranging from 65
o 3042-fold neutralisation, Fig. 2).
.4. Receptor utilisation
We  assessed the receptor utilisation of the twelve autologous
nvs isolated from SV1 by using HIV(FIV)-luc pseudotypes. While
L8 Env supported infection of cells expressing feline but not
uman CD134, the B2542 Env supported infection of cells express-
ng either feline CD134, or the feline × human CD134 chimaera,
xpressing the ﬁrst cysteine rich domain (CRD1) of feline CD134 in
he context of human CD134 [42]. In comparison with the GL8 and
2542 Envs, all SV1 Envs were highly dependent on the cysteine-
ich domain 2 (CRD2) of CD134 (Fig. 3), displaying a “GL8-like”
henotype similar to that of “early”, acute isolates of FIV that are
ikely to be transmitted in the ﬁeld [34,42,43].
. DiscussionDespite several HIV-1 vaccine efﬁcacy studies in human volun-
eers [9] and the FIV vaccine having been available commercially
or 12 years, the mechanisms of vaccine induced protection againstded; the complete neutralisation data is shown in Table 3. The dashed line indicates
re considered to be ‘strongly neutralising’. (For interpretation of the references to
lentiviral infection have not been examined in the ﬁeld. Experi-
mentally, the FIV vaccine did not protect cats against heterologous
challenge with the virulent primary GL8 isolate [22]. However,
since the natural challenge dose in FIV infection remains unde-
ﬁned, the challenge dose used in experimental studies might be
too stringent.
We hypothesised that, if vaccinated cats could be identiﬁed,
we might ﬁnd evidence of subsequent infection following natural
exposure. Given that the FIV vaccine affords 80% protection [43], we
predicted that approximately 20% of vaccinated cats exposed to FIV
would become infected. Here, we  identiﬁed one cat, SV1, which had
been vaccinated and tested provirus positive. SV1 had been vacci-
nated against FIV annually for at least three years, with the last
vaccination administered three months prior to FIV diagnosis and
death.
Phylogenetic analysis of full length env sequences revealed that
cat SV1 was infected with a recombinant clade A/B isolate of FIV,
the major parent being related to the Clade A isolate GL8. Further-
more, the receptor utilisation phenotype of the SV1 Env variants
resembled that of GL8, characteristic of the phenotype displayed by
“early” isolates circulating during the acute phase of infection and
requiring the CRD2 domain of CD134 for infection [44,45]. Hence
it is likely that the Env variants isolated from SV1 had been trans-
mitted recently, raising the question: were the immune responses
induced by FIV vaccination insufﬁcient to protect cat SV1 against
infection with a recombinant virus displaying the “acute” phe-
notype? The incomplete medical history of this case prevents a
deﬁnitive conclusion, since the vaccination and FIV status of cat
SV1 prior to 2006 was  not documented and so it is possible that
the cat could have been infected prior to vaccination. The incom-
plete medical history of cat SV1 highlights the challenges faced in
assessing vaccine efﬁcacy in the ﬁeld; the compliance of owners
and veterinarians in providing detailed clinical histories and in fol-
lowing the recommendations of the vaccine manufacturer cannot
be assumed in real life situations. It is the responsibility of veterin-
arians to provide information to owners pertaining to the risks and
beneﬁts of vaccination and to emphasise that cats should always
be tested for FIV infection prior to vaccination.
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Fig. 3. A panel of cell lines bearing chimaeric human × feline CD134 molecules was used to assess receptor usage by 12 pseudotypes bearing Envs from cat SV1. CD134
consists of 3 CRDs; HHH represents MCC  cells expressing the entire human CD134, while CLL-CD134 represents cells expressing the entire feline CD134. These constructs
served as negative and positive controls, respectively. FFF represents MCC  cells expressing feline CD134 while FFH represents MCC  cells expressing a chimeric feline/human
CD134  with the CRD2 domain comprising the human sequence. These cells are permissible for entry of prototypic “late” isolates of FIV such as B2542 [44] which are CRD2
independent. Pseudotypes bearing GL8 and B2542 Envs were tested in parallel as representative “early” and “late” pseudotypes, respectively. Each bar represents mean
luciferase activity (cpm) ± standard error (n = 3). The luciferase activity of pseudotypes on MCC  cells expressing the CD134 chimaera containing the human CRD2 domain
(FFH;  grey bars) determined the subsequent pseudotype classiﬁcation. All of the pseudotypes bearing SV1 Envs shared similar phenotypes with the pseudotypes bearing the
Env  of the “early”, CRD2-dependent GL8 strain.
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nUsing a rare panel of plasma samples from Australian cats vac-
inated against FIV, we assessed the breadth and potency of NAbs
nduced by vaccination. None of the plasma samples displayed
road cross-reactivity against a panel of pseudotypes bearing Envs
rom either reference or ﬁeld isolates. Only 50% of the vaccinated
ats strongly neutralised the pseudotype bearing KKS Env, the
equence of which closely resembles that of FIV-Petaluma [33],
ne component of the divalent FIV vaccine [21]. A strong NAb
esponse had been proposed as a correlate of protection [46,47]
nd a crucial component of humoral immunity against virus infec-
ions [48,49]. Initial studies reported that NAbs recognising the
omologous Petaluma and Shizuoka strains were detected in most
accinated cats and eight of twelve vaccinated cats neutralised the
eterologous FIV Bangston isolate, leading to the conclusion that
he two isolates of FIV within the vaccine might act synergistically
o enhance the development of NAbs against heterologous strains
f FIV [2]. However, another study suggested that vaccine induced
Abs might not be a crucial component of FIV vaccine induced
mmunity [50], because strong NAb responses were elicited in only
hree of ten vaccinated cats.
It is possible that plasma SV1 strongly neutralised all of the
utologous pseudotypes as a result of antigenic stimulation fol-
owing FIV infection. It was demonstrated experimentally that,
ollowing challenge with the virulent primary GL8 isolate, viral
oads in vaccinated cats were signiﬁcantly enhanced compared to
on-vaccinated controls [22]. Given the onset of severe clinical
igns in SV1, it could be speculated that vaccination had led to
nhanced infection, followed by antigenic hyper-stimulation and
ence a robust autologous NAb response might have resulted from
he immune system having been primed by vaccination. Insufﬁ-
ient sample was available to assess the plasma viral loads in cat
V1 to test this hypothesis.It is unclear whether sterilising immunity following FIV vac-
ination can be achieved in the absence of broadly cross-reactive
Abs. Mechanisms of blocking retroviral infection other than direct
eutralisation of free viral particles, including antibody dependentcell mediated cytotoxicity (ADCC), antibody dependent cell medi-
ated viral inhibition (ADCVI) [51] and cellular immunity, which
also play roles in controlling retroviral infections were not stud-
ied here. Although cellular immunity is important for controlling
retroviral infections [52], HIV vaccine candidates eliciting cellular
immunity have been ineffective [53–55]. However, FIV vaccination
elicits strong adaptive T cell immunity [21], protecting cats against
homologous challenge in the absence of NAbs [56].
The present study highlights the need for rigorous evaluation
of the FIV vaccine and the challenges associated with such stud-
ies under ﬁeld conditions. The small number of cats tested and the
lack of detailed clinical histories for some of them limit the con-
clusions that can be drawn from the study and demonstrate that
a larger number of subjects will be required to comprehensively
assess vaccine efﬁcacy in the ﬁeld.
5. Conclusions
This study demonstrated that FIV vaccination induces NAbs
against one of the vaccine strains in the majority of vaccinates,
potentially a useful marker to identify cats likely to be protected
following challenge. Since immune correlates of protection against
FIV vaccination remain incompletely understood and recombinant
strains of FIV in the ﬁeld are abundant [57], further studies are warr-
anted to fully assess FIV vaccine efﬁcacy under ﬁeld conditions.
Given the failure of phase III HIV vaccine clinical trials [10–15] and
the increased risk of HIV acquisition in some cases [16], are fur-
ther trials on human volunteers justiﬁed before the mechanisms
of protection induced by FIV vaccination have been identiﬁed?
It is apparent that differences between FIV and HIV-1 are more
profound than those between HIV-1 and its simian counterpart.
Paradoxically, these differences, and the fact that FIV has coexisted
with its natural host for longer than HIV-1, may  prove crucial to
better understanding the interplay between lentiviruses and their
hosts and to developing an effective human lentiviral vaccine.
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